Aurobindo Pharma is set to boost Penicillin-G output to over 10,000 metric tonnes annually. Its China manufacturing facility is projected to reach EBITDA break-even this quarter. The company is also advancing its US operations and developing complex generics. These strategic moves aim for sustainable growth and improved profitability.